ALNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Alnylam Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was -20.38%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Alnylam Pharmaceuticals's 10-Year ROIIC % or its related term are showing as below:
The historical data trend for Alnylam Pharmaceuticals's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
10-Year ROIIC % | Get a 7-Day Free Trial | -153.08 | -78.56 | -67.98 | -79.82 | -20.38 |
Alnylam Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
10-Year ROIIC % | Get a 7-Day Free Trial | - | -20.38 | - | - | - |
For the Biotechnology subindustry, Alnylam Pharmaceuticals's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's 10-Year ROIIC % falls into.
Alnylam Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
10-Year ROIIC % | = | 10-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 10-Year Incremental Invested Capital** |
= | ( -286.5487125 (Dec. 2023) - -90.2187994 (Dec. 2013) ) | / | ( 1168.607 (Dec. 2023) - 205.132 (Dec. 2013) ) | |
= | -196.3299131 | / | 963.475 | |
= | -20.38%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Alnylam Pharmaceuticals (NAS:ALNY) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tolga Tanguler | officer: EVP, Chief Commercial Officer | 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142 |
Yvonne Greenstreet | officer: EVP, Chief Commercial Officer | PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Jeffrey V. Poulton | officer: Chief Financial Officer | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Pushkal Garg | officer: CMO & EVP Dev & Med Affairs | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
Dennis A Ausiello | director | PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Amy W Schulman | director | PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Pyott David E I | director | C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612 |
Phillip A Sharp | director | BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Indrani Lall Franchini | officer: EVP, CLO & Secretary | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Michael W Bonney | director | 65 HAYDEN AVE, LEXINGTON MA 02421 |
Akshay Vaishnaw | officer: SVP, Clinical Research | 300 THIRD STREET, CAMBRIDGE MA 02139 |
Peter N Kellogg | director | MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Carolyn R Bertozzi | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
John Maraganore | director, officer: President and CEO | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocus Research • 08-02-2024
By GuruFocus News • 11-01-2024
By Business Wire • 07-18-2024
By Business Wire • 09-29-2024
By Business Wire • 09-26-2024
By GuruFocus Research • 06-24-2024
By GuruFocus News • 11-08-2024
By Business Wire • 10-17-2024
By Business Wire • 05-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.